https://www.selleckchem.com/pr....oducts/sulfatinib.ht
cterization. Phase III clinical trials of the tumour necrosis factor inhibitors SB4, SB2, and SB5 (biosimilars to etanercept, infliximab, and adalimumab, respectively) have demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA). Data from these trials were used to identify baseline characteristics associated with radiographic progression and to build a matrix risk model for its prediction. Patients with radiographic progression and baseline demographic and disease characteristic data were pooled across the 3 phase III
Like
Comment
Share
